Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B- 22

Journal of Clinical Oncology

Volumn 15, Issue 5, 1997, Pages 1858-1869

  Fisher, Bernard ^a   Anderson, Stewart ^a   Wickerham, D Lawrence ^a   DeCillis, Arthur ^a   Dimitrov, Nikolay ^a   Mamounas, Eleftherios ^a   Wolmark, Norman ^a   Pugh, Reginald ^a   Atkins, James N ^a   Meyers, Frederick J ^a   Abramson, Neil ^a   Wolter, Janet ^a   Bornstein, Richard S ^a   Levy, Lawrence ^a   Romond, Edward H ^a   Caggiano, Vincent ^a   Grimaldi, Manuel ^a   Jochimsen, Peter ^a   Deckers, Peter ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; TAMOXIFEN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; HEMORRHAGIC CYSTITIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS;

EID: 0030913595     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.5.1858     Document Type: Article

References (28)

1. DeVita VT: Dose-response is alive and well. J Clin Oncol 4:1157-1159, 1986
2. Hryniuk W, Bush H: The importance of dose-intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2:1281-1288, 1984
3. Hryniuk W: More is better. J Clin Oncol 6:1365-1367, 1988
4. Tannock IF, Boyd NF, DeBoer G, et al: A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 6:1377-1387, 1988
5. Hryniuk W, Levine MN, Levin L: Analysis of dose intensity for chemotherapy in early (stage II) and advanced breast cancer. NCI Monogr 1:87-94, 1986
6. Hryniuk W, Levine MN: Analysis of dose-intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 4:1162-1170, 1986
7. Henderson IC, Hayes DF, Gelman R: Dose-response in the treatment of breast cancer: A critical review. J Clin Oncol 6:1501-1515, 1988
8. Korzun A, Norton L, Perloff M, et al: Clinical equivalence despite dosage differences of two schedules of cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisone (CMFVP) for adjuvant therapy of node-positive stage II breast cancer. Proc Am Soc Clin Oncol 7:12, 1988 (abstr)
9. Ludwig Breast Cancer Study Group: A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. Cancer Res 45:4454-4459, 1985
10. Fisher B, Fisher ER, Redmond C: Ten-year results from the NSABP clinical trial evaluating the use of L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. J Clin Oncol 4:929-941, 1986
11. Fisher B, Redmond C, Brown A, et al: Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med 305:1-6, 1981
12. Cutler SJ, Ederer F: Maximum utilization of the life table method in analyzing survival. J Chronic Dis 8:699-712, 1958
13. Lewis JA, Machin D: Intention to treat - Who should use ITT? Br J Cancer 68:647-650, 1993
14. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
15. Hankey BF, Myers MH: Evaluating differences in survival between two groups of patients. J Chronic Dis 24:523-531, 1971
16. Peto R, Peto J: Asymptotically efficient rank invariant test procedures. J R Stat Soc [A] 135:185-206, 1972
17. Von Hoff DD, Clark GM, Weiss GR, et al: Use of in vitro dose-response effects to select antineoplastics for high-dose or regional administration regimens. J Clin Oncol 4:1827-1834, 1986
18. Frei III E, Canellos GP: Dose, a critical factor in cancer chemotherapy. Am J Med 69:585-594, 1980
19. Frei III E, Antman K, Teicher B, et al: Bone marrow autotransplantation for solid tumors-prospects. J Clin Oncol 7:515-526, 1989
20. Vahdat L, Antman K: High-dose therapy for breast cancer. Blood Reviews 9:191-200, 1995
21. Triozzi PL, Rhoades C, Thornton DE: High-dose chemotherapy for breast cancer. Cancer Treat Rev 21:185-198, 1995
22. Fisher B, Brown AM, Dimitrov NV, et al: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with six months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from NSABP B-15. J Clin Oncol 8:1483-1496, 1990
23. Fisher B, Redmond C, Legault-Poisson S, et al: Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from NSABP B-16. J Clin Oncol 8:1005-1018, 1990
24. Hryniuk WM: Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 14:65-74, 1987
25. Steward WP: High dose chemotherapy with haemopoietic support for breast cancer. Eur J Cancer 31A:S21-S24, 1995 (suppl 7)
26. Kennedy MJ: High-dose chemotherapy of breast cancer: Is the question answered? J Clin Oncol 13:2477-2479, 1995 (editorial)
27. Souhami RL: Will increases in dose intensity improve outcome: Con. Am J Med 99:6A-71S-6A-76S, 1995 (suppl 6A)
28. Wood WC, Budman DR, Korzun AH, et al: Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330:1253-1259, 1994